Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,342 | $1,413 | $1,489 | $2,806 |
| - Cash | $150 | $127 | $206 | $148 |
| + Debt | $60 | $11 | $120 | $117 |
| Enterprise Value | $1,252 | $1,297 | $1,403 | $2,775 |
| Revenue | $258 | $117 | $112 | $383 |
| % Growth | 120.5% | 4.5% | -70.8% | – |
| Gross Profit | $258 | $117 | $112 | $383 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$269 | -$291 | -$258 | $59 |
| % Margin | -104.3% | -248.7% | -230.4% | 15.4% |
| Net Income | -$283 | -$307 | -$267 | $53 |
| % Margin | -109.7% | -262.4% | -238.4% | 13.8% |
| EPS Diluted | -3.14 | -4.15 | -3.71 | 0.71 |
| % Growth | 24.3% | -11.9% | -622.5% | – |
| Operating Cash Flow | -$170 | -$306 | $438 | -$256 |
| Capital Expenditures | -$6 | -$24 | -$6 | -$26 |
| Free Cash Flow | -$176 | -$330 | $432 | -$282 |